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Why study the economics of screening for CF?Recent advances in the medical care of people of all ages
with Cystic Fibrosis (CF) have been associated with longer life
expectancy and improved quality of life. Newborn screening
has been shown to improve long-term outcomes and reduce
long-term care costs sufficiently to cover the costs of
implementing a newborn screening programme [1,2]. Improve-
ments in outcomes are accompanied by changing costs of care,
as well as better quality of life, but CF is likely to continue to be
a costly illness with patients experiencing less than good
quality of life for a large part of their life span [3]. With the
arrival of genetic tests of carrier status, we now have the
technology for parents to choose to avoid giving birth to
children affected by CF. The ethical debate that has followed
the arrival of genetic tests is resolved sufficiently that it is
socially acceptable in many countries to offer the test. Should
this be a technology to be widely adopted by health systems?
There are always limited funds for health care, viewed from
whatever perspective, and so choices are inevitable. Over the
past decade, health care funding agencies have increasingly
sought evidence for their decisions from economic analysis,
and there are now internationally accepted guidelines for such
work. The study by Norman and colleagues in this journal [4] is
an example of the type of analysis that might be sought in the
decision on adoption of pregnancy screening for CF.
Assessing the economic benefits of alternative approaches to
CF care requires a good understanding of the effects of care on
health outcomes, the costs of the intervention, the long term
costs of care, and the quality of life experienced by those
treated under the alternative approaches. Economics studies are
often commissioned before clinical trials and detailed long-term
data are commissioned, to help decision makers predict the
likely cost benefit given the current knowledge. It is important
to be sceptical, but not to reject all economic modelling out of
hand. The modelling methods used to estimate the economic
benefit can be more or less sophisticated, but they are almost
always based on uncertain assumptions and limited data, often1569-1993/$ -see front matter © 2012 Published by Elsevier B.V. on behalf of Eur
doi:10.1016/j.jcf.2012.05.009adapting and combining data found in systematic reviews, other
comprehensive literature searches and patient databases. A
well-conducted model aims to be as transparent and replicable
as possible, and identifies and explores the assumptions and
shows how sensitive the results of the model are. But any single
modelling exercise should be considered as a single projection
of a range of possible answers and, where possible compared
with other similar exercises as a form of validation.
The predictions, by Norman and colleagues, of the potential
economic benefit of couple screening for CF carrier status in an
Australian state are made using clearly described methods and
sources, reasonable assumptions and tests for uncertainty.
Whilst it is difficult to generalise from a model derived for a
specific location, it is an example of the form of analysis that
could be replicated in many places in the world using local
values as parameters. I predict that the resulting advice to health
commissioners would be similar.References
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